News

The balance of acids and bases in the urine of people with cystic fibrosis (CF) reflects lung and pancreas function, and the response to treatment, a study finds. The findings support measuring the bicarbonate base in urine, which mirrors the levels of various acids, as a tool to clinically…

A Phase 1b study that’s evaluating the safety of RCT2100, ReCode Therapeutics‘ investigational genetic medicine for people with cystic fibrosis (CF), has dosed its first patient. The inhalation therapy is being developed for CF patients who don’t respond to CFTR modulator therapies. “The initiation of our Phase…

A next-generation vest to help clear airway mucus in adults and children with cystic fibrosis (CF) or other lung disorders has been launched by its maker, Baxter International. Called The Vest Advanced Pulmonary Experience (APX), the garment was redesigned in consultation with clinicians and patients, and incorporates the…

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to ETD001, an investigational therapy aiming to improve mucus clearance in people with cystic fibrosis (CF). The designation is awarded by the FDA to aid the development of treatments for serious or life-threatening rare diseases —…

Mucus-producing cells in people with cystic fibrosis (CF) have lower levels of ST3Gal1, an enzyme that sugarcoats mucus to make it less thick and sticky, but treatment with Trikafta can partly restore the enzyme and make mucus easier to clear away. The findings, from a study led by…

Non-white Canadians with cystic fibrosis (CF) have a higher risk of death than white Canadians with the disease, according to a study of nearly 6,000 people with CF. Despite having similar characteristics at diagnosis and similar rates of CF complications, non-white CF patients also had worse lung function,…

In laboratory experiments, a team of researchers in Belgium identified a few strategies that might help prevent bacteria from forming treatment-resistant clusters called biofilms that are believed to underlie chronic rhinosinusitis (CRS) — an inflammatory condition affecting the nasal passages and…

Detecting Nocardia bacteria doesn’t necessarily indicate therapy is needed for people with cystic fibrosis (CF), but an active infection should be closely monitored and patients with lung involvement, a decrease in lung function, or who are undergoing a pulmonary transplant should be treated, a review study suggests.

Long-term treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) led to significant gains in lung function and nutritional status for cystic fibrosis (CF) patients with advanced lung disease, a real-world analysis shows. The improvements weren’t as large as those seen in patients with milder lung disease, but the findings demonstrate the…

Lung function decline slowed consistently over five years with Kalydeco (ivacaftor) treatment in adults and children with cystic fibrosis (CF), a real-world study in the U.S. shows. “Overall, these results expand on those from prior studies and show that [Kalydeco] has a meaningful and sustained impact on reducing…